Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 17, 2021
Reporting Period: This filing does not cover a specific financial period but announces upcoming events and the scheduled release of results for the fiscal year ended June 30, 2021.
Key Financial Metrics
This filing does not contain specific financial data. The text explicitly states that financial results for the fiscal year ended June 30, 2021, will be reported on Friday, September 24, 2021. Consequently, revenue, profit, cash flow, margins, debt, and liquidity figures are not provided in this document.
Material Changes
No material financial changes or operational updates are detailed in this filing. The document serves solely to disclose upcoming corporate communications and the timing of the next earnings release.
Guidance, Outlook, and Management Commentary
- Upcoming Presentation: CEO Eric A. Adams and BayMedica Inc. Co-Founder Shane Johnson are scheduled to present at Tribe Public's Webinar titled "Accelerating The Commercialization of Rare Cannabinoids."
- Earnings Release Date: The Company announced it will report financial results for the fiscal year ended June 30, 2021, on September 24, 2021.
- Legal Status: The information provided, including news releases (Exhibits 99.1 and 99.2), is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the actual financial results for the fiscal year ended June 30, 2021, once released on September 24, 2021.
- Review the content of the "Accelerating The Commercialization of Rare Cannabinoids" webinar for strategic updates.
- Confirm the status of the Company's emerging growth company designation (indicated as yes in the filing).